A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate different doses of the investigational immunotherapy drug INCAGN01876 in patients with advanced or metastatic solid tumors that continue to grow despite prior therapy or cannot be treated with standard therapies. INCAGN01876 is an antibody that binds to the GITR protein on immune cells called T cells. It is designed to stimulate T cells to find and kill cancer cells.
INCAGN01876 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced or metastatic solid tumor that has continued to grow despite prior therapy or cannot be treated with standard therapies.
- Patients must recover from the serious side effects of prior therapies before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Alexandra Snyder Charen at 646-888-5122.